Author

E. Meduri

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:gene regulatory network inference· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

G. Giotopoulos· 3 shared S. J. Horton· 3 shared B. J. Huntly· 2 shared D. Sasca· 2 shared F. Basheer· 2 shared H. Yun· 2 shared P. Gallipoli· 2 shared S. Agrawal-Singh· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

G. Giotopoulos

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Genetic or pharmacological inactivation of CREBBP sensitizes B-cell Acute Lymphoblastic Leukemia to Ferroptotic Cell Death upon BCL2 Inhibition

A. Garcia-Gimenez, J. E. Ditcham, D. M. A. Azazi, E. Meduri, R. Asby, N. Sakakini, C. K. Lopez, N. Narayan, T. Beinortas, J. Bagri, S. Agrawal Singh, G. Giotopoulos, M. P. Murphy, S. J. Horton, B. Huntly, S. E. Richardson

This study identifies CREBBP mutations as a targetable vulnerability in B-ALL, showing that CREBBP inhibition sensitizes these cells to Venetoclax-induced ferroptosis.

bioRxiv · Oct 2, 2023 · PreprintCancer Biology

MAT2A inhibition in AML unveils therapeutic potential of combining DNA demethylating agents with UPR targeting

K. Zeka, A. V. Taylor, R. Samarista, D. Ragusa, C.-W. Suen, O. W. Cyran, A. F. Domingues, E. Meduri, B. J. Huntly, D. Forte, A. Curti, C. Pina

The paper shows that combining DNA demethylating agents with UPR targeting improves AML cell suppression beyond single-agent therapies.

bioRxiv · Jun 5, 2023 · PreprintCancer Biology

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 co-activation

V. Shah, G. Giotopoulos, H. Osaki, M. Meyerhoefer, E. Meduri, B. Schubert, H. Yun, S. J. Horton, S. Agrawal-Singh, P. S. Haehnel, F. Basheer, D. Lugo, M. W. Kuehn, B. Guezguez, M. Theobald, , D. Sasca

This study identifies p300-mediated compensatory transcriptional programs that drive acute resistance to BET inhibitors in AML and suggests sequential BET- and p300-inhibition as a therapeutic strategy.

bioRxiv · Sep 14, 2022 · PreprintCancer Biology

Mutational synergy coordinately remodels chromatin accessibility, enhancer landscape and 3-Dimensional DNA topology to alter gene expression during leukemia induction

H. Yun, S. Vohra, A. Mupo, G. Giotopoulos, D. Sasca, S. J. Horton, S. Agrawal-Singh, E. Meduri, F. Basheer, L. Marando, M. Gozdecka, O. M. Dovey, A. Castillo-Venzor, X. Wang, P. Gallipoli, , B. J. P. Huntly

The paper investigates how mutations synergize to alter chromatin accessibility, enhancer landscapes, and 3D DNA topology in leukemia induction using a murine model.

bioRxiv · Mar 20, 2020Cancer Biology